Evidence map›Paper›PMID 27271989›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection.

Abdel-Rahman Nabawy Zekri, Amira Salah El-Din Youssef, Eman Desouky El-Desouky, Ola Sayed Ahmed, Mai M Lotfy, Auhood Abdel-Monem Nassar, Abeer A Bahnassey

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Abdel-Rahman Nabawy ZekriMolecular Virology and Immunology Unit, Cancer biology Department, National Cancer Institute, Cairo University, Cairo, Egypt. ncizekri@yahoo.com.
Amira Salah El-Din YoussefMolecular Virology and Immunology Unit, Cancer biology Department, National Cancer Institute, Cairo University, Cairo, Egypt. amira.salah@nci.cu.edu.eg.
Eman Desouky El-DesoukyEpidemiology and Biostatistics Unit, Epidemiology and Biostatistics Department, National Cancer Institute, Cairo, Egypt.
Ola Sayed AhmedMolecular Virology and Immunology Unit, Cancer biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Mai M LotfyMolecular Virology and Immunology Unit, Cancer biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Auhood Abdel-Monem NassarMolecular Virology and Immunology Unit, Cancer biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Abeer A BahnasseyPathology Department, National Cancer Institute, Cairo University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification of new high-sensitivity and high-specificity markers for hepatocellular carcinoma (HCC) is essential. We aimed at identifying serum microRNAs (miRNAs) as potential biomarkers for early detection of HCC on top hepatitis C virus (HCV) infection. We investigated serum expression of 13 miRNAs in 384 patients with HCV-related chronic liver disease (192 with HCC, 96 with liver cirrhosis (LC), and 96 with chronic hepatitis C (CHC)) in addition to 96 healthy participants enrolled as a control group. The miRNA expression was performed using real-time quantitative PCR-based SYBR Green custom miRNA arrays. The area under the receiver operating characteristic curve (AUC) was used to evaluate the diagnostic performance of miRNA panels for early detection of HCC. Using miRNA panel of miR-122, miR-885-5p, and miR-29b with alpha fetoprotein (AFP) provided high diagnostic accuracy (AUC = 1) for early detection of HCC in normal population while using miRNA panel of miR-122, miR-885-5p, miR-221, and miR-22 with AFP provided high diagnostic accuracy (AUC = 0.982) for early detection of HCC in LC patients. However, using miRNA panel of miR-22 and miR-199a-3p with AFP provided high diagnostic accuracy (AUC = 0.988) for early detection of HCC in CHC patients. We identified serum miRNA panels that could have a considerable clinical use in early detection of HCC in both normal population and high-risk patients.

Indexed as

AdultAgedAged, 80 and overalpha-FetoproteinsBiomarkers, TumorCarcinoma, HepatocellularCase-Control StudiesEarly DiagnosisFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHepacivirusHepatitis C, ChronicHumansLiver NeoplasmsMalealpha-FetoproteinsBiomarkers, TumorMicroRNAsEarly detectionHCCHCVmiRNAsPanelSerum

Identifiers

PMID27271989

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.